VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.8%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$237M
AUM Growth
-$4.18M
(-1.7%)
Cap. Flow
-$15.8M
Cap. Flow
% of AUM
-6.66%
Top 10 Holdings %
Top 10 Hldgs %
7.93%
Holding
416
New
61
Increased
247
Reduced
47
Closed
61
Top Buys
| 1 |
EOG Resources
EOG
|
$2.02M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.99M |
| 3 |
ConocoPhillips
COP
|
$1.85M |
| 4 |
Imperial Oil
IMO
|
$1.8M |
| 5 |
Reliance Steel & Aluminium
RS
|
$1.76M |
Top Sells
| 1 |
Ryman Hospitality Properties
RHP
|
$2.57M |
| 2 |
Western Midstream Partners
WES
|
$2.52M |
| 3 |
INN
Summit Hotel Properties
INN
|
$2.43M |
| 4 |
Brookfield Renewable
BEPC
|
$2.38M |
| 5 |
Grupo Aeroportuario del Pacifico
PAC
|
$2.16M |
Sector Composition
| 1 | Healthcare | 30.46% |
| 2 | Real Estate | 18.03% |
| 3 | Energy | 13.68% |
| 4 | Materials | 11.34% |
| 5 | Utilities | 10.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IGMS
276
DELISTED
IGM Biosciences
IGMS
| $263K | 0.11% |
3,434
+60
| +2% | +$4.6K |
|
277
Kodiak Sciences
KOD
$549M
| $262K | 0.11% |
2,308
+40
| +2% | +$4.54K |
|
278
Arcus Biosciences
RCUS
$1.24B
| $262K | 0.11% |
9,348
+160
| +2% | +$4.48K |
|
279
Stellus Capital Investment Corp
SCM
$420M
| $260K | 0.11% |
20,469
+2,269
| +12% | +$28.8K |
|
280
Amicus Therapeutics
FOLD
$2.49B
| $259K | 0.11% |
26,201
+714
| +3% | +$7.06K |
|
|
ALBO
281
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $258K | 0.11% |
7,326
+134
| +2% | +$4.72K |
|
282
Fate Therapeutics
FATE
$113M
| $256K | 0.11% |
3,110
+49
| +2% | +$4.03K |
|
|
MYOV
283
DELISTED
Myovant Sciences Ltd.
MYOV
| $256K | 0.11% |
12,457
+221
| +2% | +$4.54K |
|
284
Regenxbio
RGNX
$485M
| $255K | 0.11% |
7,478
+139
| +2% | +$4.74K |
|
285
Phathom Pharmaceuticals
PHAT
$858M
| $254K | 0.11% |
6,753
+118
| +2% | +$4.44K |
|
|
RETA
286
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $253K | 0.11% |
2,537
+39
| +2% | +$3.89K |
|
287
Zentalis Pharmaceuticals
ZNTL
$121M
| $252K | 0.11% |
5,819
+108
| +2% | +$4.68K |
|
288
Monroe Capital Corp
MRCC
$163M
| $250K | 0.11% |
24,915
-579
| -2% | -$5.81K |
|
289
Seres Therapeutics
MCRB
$190M
| $249K | 0.11% |
605
+10
| +2% | +$4.12K |
|
290
Mirum Pharmaceuticals
MIRM
$3.9B
| $248K | 0.1% |
12,515
+223
| +2% | +$4.42K |
|
291
Apellis Pharmaceuticals
APLS
$3.5B
| $247K | 0.1% |
5,761
+93
| +2% | +$3.99K |
|
292
Cogent Biosciences
COGT
$1.77B
| $247K | 0.1% |
+28,101
| New | +$247K |
|
293
CRISPR Therapeutics
CRSP
$5B
| $244K | 0.1% |
2,003
+37
| +2% | +$4.51K |
|
294
NextCure
NXTC
$13.2M
| $244K | 0.1% |
2,035
+36
| +2% | +$4.32K |
|
|
CCXI
295
DELISTED
ChemoCentryx, Inc.
CCXI
| $244K | 0.1% |
4,769
+75
| +2% | +$3.84K |
|
296
Rocket Pharmaceuticals
RCKT
$346M
| $238K | 0.1% |
5,361
+100
| +2% | +$4.44K |
|
297
FibroGen
FGEN
$44M
| $237K | 0.1% |
273
+4
| +1% | +$3.47K |
|
298
Relay Therapeutics
RLAY
$690M
| $237K | 0.1% |
6,849
+117
| +2% | +$4.05K |
|
299
Keros Therapeutics
KROS
$621M
| $236K | 0.1% |
3,835
+77
| +2% | +$4.74K |
|
300
Q32 Bio
QTTB
$20.6M
| $236K | 0.1% |
1,394
+25
| +2% | +$4.23K |
|